In today’s world a well-crafted product requires a sound value-driven story backed by articulate evidence and quality data. Putnam has supported a range of clients from venture-backed start-ups to the largest global biopharmaceutical companies in the world to develop actionable data and evidence driven Value, Pricing & Access strategies to meets evolving payer and stakeholder needs. We help clients develop holistic pricing strategies and capabilities that support growth and optimize value. With deep and extensive knowledge of global market access issues, our global Value, Pricing & Access practice supports client teams at all points in the product development lifecycle from discovery through post-launch with:

• Understanding the Current and Evolving Access Landscape and Stakeholder Perspectives
• Defining, Substantiating and Communicating Value to Economic Stakeholders
• Developing Pricing, Contracting, and Access Strategies to Maximize Value
• Developing and Refining Economic Stakeholder Engagement Strategies and Tools

Underlying our Value Pricing & Access Strategy Guidance is Expertise in Key Disciplines

Deep Experience & Rigorous Strategic Perspective : Drawing on Deep Expertise and Framing Issues from a Strategic Perspective to produce client impact

Primary Market Research With Access Decision Makers: Developing Primary Market Intelligence that Digs Deeper to Unlock Winning Strategies

Advanced Pricing & Access Scenario Modeling Capabilities: Quantifying Complex Tradeoffs and Scenarios to Produce Clarity and Arrive at Optimal Pricing and Contracting Strategies

Successfully bringing a new product to market requires a comprehensive understanding of the clinical landscape to achieve commercial success. This is especially true for novel products and complex or dynamic therapeutic areas. Our New Product Strategy practice brings an interdisciplinary approach and a strategic mindset to support clients in making optimal decisions as products advance through the clinical towards market approval and commercialization.

• Understanding full market opportunity including key decision stakeholders and the roles they play to provide treatment to patients
• Product positioning and clinical differentiation
• Registrational trial design
• Go-to market model development and engagement
• Launching KPI identification and tracking
• Planning for diagnostics, combination therapies, and other enablers

Supporting Our New Product Strategy is Functional Expertise in Key Areas

• Clinical & Scientific Expertise: Understanding the HOW related to clinical asset positioning 
• Primary Market Research: Investigating the WHY around customer decision making 
• Patient Opportunity & Forecast Modeling: Quantifying the IMPACT on business opportunity

Our Established Product Strategy supports clients across the globe in maximizing product and franchise performance for inline brands. Our broad project portfolio spans every therapeutic category, and we have served many of the largest or fastest growing products of the past decade. We partner with client teams to design solutions with the strategic goal in mind, by re-defining the problem for the client in novel ways, and ensuring the right questions are asked so the answers lead to impact

• Understanding and identifying market opportunities
• Re-invigorating growth to realize full potential
• Tracking performance and pursuing evolving opportunities in dynamic markets
• Planning for and defending against competitive interests
• Matching portfolios and engagement strategies with the needs of diverse set HCP stakeholders
• Designing lifecycle management strategies

Supporting our Established Product Strategy is Functional Expertise in Key Disciplines

• Data Strategy, Analytics, & Visualization: Investigating the WHAT around market dynamics
• Primary Market Research: Investigating the WHY around customer decision making
• Promotional/Engagement Strategy: Understanding the WHO and HOW around opportunity

The Putnam Medical & Scientific Affairs team brings together deep scientific expertise and rigorous problem-solving ability to support medical teams in their decision making and planning. Our projects seek to help teams deliver on the clinical value of the product/franchise and optimize the ability to bring the benefits to the appropriate patients. Key examples of how our team supports a broad range of client includes:

• Global medical plan development and dissemination/adaptation to individual countries
• Need based Evidence Generation Planning
• Clinical Development and Lifecycle Strategy
• Strategic Expert Stakeholder Engagement (to seek feedback and guidance)

Supporting our Medical & Scientific Affairs Strategy is Functional Expertise in Key Disciplines

• Clinical & Scientific Expertise: Understanding and identifying the EVIDENCE with meticulous literature reviews
• Deep Experience & Rigorous Strategic Perspective: Drawing on Deep Expertise and Framing Issues from a STRATEGIC PERSPECTIVE to produce client impact
• Clinical Outcomes Simulation Modeling: Quantifying the IMPACT on patient outcomes

Developing a robust long-term portfolio, licensing & development strategy is paramount for life sciences companies seeking to gain a competitive advantage in an industry where new innovations and breakthroughs seem to be on the constant horizon. Putnam brings a unique blend of clinical and scientific expertise, innovative business strategy and over three decades of strategic experience to advise on optimal and sustainable portfolio, licensing and development strategies for life sciences clients across the globe.

• Long term portfolio planning and optimization
• Therapeutic area landscape evolution analysis planning
• Technology & asset scans
• In-licensing/out-licensing due diligence
• Integrative strategy development that incorporates both legacy and newly acquired assets

Supporting our Portfolio, Licensing & Development Strategy is Functional Expertise in Key Disciplines

• Clinical & Scientific Expertise: Understanding the HOW related to clinical asset positioning
• Deep Experience & Rigorous Strategic Perspective: Drawing on Deep Expertise and Framing Issues from a STRATEGIC PERSPECTIVE to produce client impact
• Patient Opportunity & Forecast Modeling: Quantifying the IMPACT on business opportunity

Our Enterprise Strategy practice offers life sciences clients guidance and support in developing best in class approaches to clinical, medical and commercial operations. Putnam delivers a global team equipped to handle the complexities of identifying and executing winning global strategies. Our strategic recommendations are underpinned by rigorous evidence collection and experience in supporting leading biopharmaceutical companies for over three decades to deliver exceptional impact and value to enterprise and corporate needs.

• Portfolio-level digital and personal promotional strategy
• Corporate account engagement
• Data platform & insight mining
• R&D decision-making process optimization
• New business unit evaluation and implementation strategy
• Virtual commercial operations support

Supporting our Enterprise Strategy is Functional Expertise in Key Disciplines

• Operations Expertise/Change Management: Understanding the HOW related to clinical asset positioning
• Deep Experience & Rigorous Strategic Perspective: Drawing on Deep Expertise and Framing Issues from a Strategic Perspective to produce client impact
• Top to bottom support for all areas of enterprise: Quantifying the IMPACT on commercial opportunity

Our global Market Research practice bring rigorous answers to our clients’ most important questions. We use hypothesis-driven approaches to research design, fielding, and analysis to deliver actionable insights tailored to specific need and market context. Putnam Market Research teams have strong relationships with in-country partners that allow us to support nearly all markets and understand the market specific nuances that impact research fielding and methodological design. Our practice in the area involves:

• Qualitative Research
• Quantitative Research
• Qual / Quant “Hybrid” Research
• Focus Groups / Panels
• Asynchronous Data / Opinion Collection
• Multi-Source Data Synthesis

Supporting our Market Research Strategy is Functional Expertise in Key Disciplines

• In-Depth Qualitative Research: Understanding the WHY behind clinical decision making
• Rigorous Quantitative Research: Measuring WHAT is happening today and what future scenarios will hold
• Synthesis of Multiple Data Sources: Developing a SINGLE TRUTH of market dynamics to support strategy development

With 16 years of big data experience, and recent Data Practice expansion, Putnam brings…

• Unparalleled knowledge of the evolving data landscape, both traditional sources and emerging players
• A long track record of innovating and enhancing cutting-edge use cases to drive strategy and tactics

Projects

R&D/Early Commercial Teams

• Patient journeys, unmet need assessments, and forecasting

Brand Teams (Pre-Launch & In-Market)

• Data-source evaluation, optimization and architecture
• Rich market landscapes – tracking, dashboards, physician targeting & segmentation, predictive analytics and brand strategy

Pricing & Market Access

• Deep dives on billing & coding, charges submitted and reimbursed, and payer – Health-Care-Organization dynamics
• RWE analysis in support of Pricing & Market Access, EU Health Technology Assessments

A pioneer in CGT strategy with experience with key leaders in the field, Putnam has had a dedicated practice in this space since 2013. Our practice has covered 17 unique disease areas including hematologic malignancies (DLBCL, ALL, MM, FL), solid tumors, neurology, ophthalmology, cardiology, and benign blood disorders. Putnam’s in-house panel of CGT experts provides our teams with unfettered access to high-level KOLs, clinicians, and key administrative decision-makers (CMOs, SVPs, CFOs) at leading US medical centers. Our robust experience and industry leading breadth and depth across client types, diseases areas and technologies within this space allows us to support a wide array of CGT specific engagements:

• Commercial Opportunity Assessment
• Market Access & Pricing Strategy
• Business Development & Portfolio Planning
• Operations Customer Experience

When it comes to cell and gene therapy, Putnam knows…

Who to Talk to

Putnam’s research does not stop with HCPs. We understand the importance and influence of stakeholders across the CGT ecosystem

• Recent Putnam CGT research samples have included :
• Disease therapy experts
• CAR-T / gene therapy experts
• Nurse navigators
• Program administrators
• Hospital CFOs decision makers
• Lab Directors / Technicians
• IT decision makers and system end-users
• Billing specialists
• Patient support specialists

How to Find Them

Putnam has the right tools in our research “toolbox” and we know the right time to use each one

• When it comes to data collection, we can turn to:
• Our roster of 20+ third-party sample partners (each with their own strengths)
• Our general internal panel of HCPs, Payers, and other
• Our specialized CGT focused panel of high-level KOLs that were selected specifically for their experience in the field
• Technologies that allow us to find and reach new stakeholders

How to Talk to Them

Putnam’s consultant possess a rich understanding of the CGT space, allowing them to hold deeper and more engaging conversations with CGT experts

Our expertise in the space also gives us a greater ability to identify and probe into those small details that firms with less experience in the CGT space may miss